Details of the Drug

General Information of Drug (ID: DM4W9B3)

Drug Name

Fosamprenavir

Synonyms

Telzir; Amprenavir phosphate; Fosamprenavir [INN]; GW 433908; GW433908; VX 175; Fosamprenavir (INN); Lexiva (TM); Lexiva (TN); Telzir (TN); Telzir(TM); VX-175; GW433908A (*Sodium Salt*); GW433908G (*Calcium Salt*); [(3S)-oxolan-3-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-1-phenyl-3-phosphonooxybutan-2-yl]carbamate; Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-1-(phenylmethyl)-2-(phosphonooxy)propyl)-, C-((3S)-tetrahydro-3-furanyl) ester; ((3S)Oxolan-3-yloxy)-N-((1S,2R)-3-{[(4-aminophenyl)sulfonyl](2-methylpropyl)amino}-1-benzyl-2-(phosphonooxy)propyl)carboxamide; (3-(((4-Aminophenyl)sulfonyl)(2-methylpropyl)amino)-1-(phenylmethyl)-2-(phosphonooxy)propyl)carbamic acid C-(tetrahydro-3-furanyl) ester

Indication

Disease Entry	ICD 11	Status	REF
Human immunodeficiency virus infection	1C62	Approved	[1]
------------------------------------------------------------------------------------

Therapeutic Class

Anti-HIV Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 3

Molecular Weight (mw)

585.6

Logarithm of the Partition Coefficient (xlogp)

1.8

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [2]
Elimination: 0% of drug is excreted from urine in the unchanged form [2]
Half-life: The concentration or amount of drug in body reduced by one-half in 7.7 hours [3]
Metabolism: The drug is metabolized via the liver []
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 67.80681 micromolar/kg/day [4]
Water Solubility: The ability of drug to dissolve in water is measured as 0.31 mg/mL [2]

Chemical Identifiers

Formula: C25H36N3O9PS
IUPAC Name: [(3S)-oxolan-3-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-1-phenyl-3-phosphonooxybutan-2-yl]carbamate
Canonical SMILES: CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CCOC2)OP(=O)(O)O)S(=O)(=O)C3=CC=C(C=C3)N
InChI: InChI=1S/C25H36N3O9PS/c1-18(2)15-28(39(33,34)22-10-8-20(26)9-11-22)16-24(37-38(30,31)32)23(14-19-6-4-3-5-7-19)27-25(29)36-21-12-13-35-17-21/h3-11,18,21,23-24H,12-17,26H2,1-2H3,(H,27,29)(H2,30,31,32)/t21-,23-,24+/m0/s1
InChIKey: MLBVMOWEQCZNCC-OEMFJLHTSA-N

Cross-matching ID

PubChem CID: 131536
ChEBI ID: CHEBI:82941
CAS Number: 226700-79-4
DrugBank ID: DB01319
TTD ID: D0F5MT
VARIDT ID: DR01274
INTEDE ID: DR0745
ACDINA ID: D00292

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Human immunodeficiency virus Protease (HIV PR)	TT5FNQT	POL_HV1B1	Inhibitor	[5]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[6]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[7]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Fosamprenavir

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
MK-1439	DM215WE	Minor	Decreased metabolism of Fosamprenavir caused by MK-1439 mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[8]
Fostemsavir	DM50ILT	Moderate	Decreased metabolism of Fosamprenavir caused by Fostemsavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[9]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Fosamprenavir caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[10]
Dolutegravir	DMCZGRE	Major	Increased metabolism of Fosamprenavir caused by Dolutegravir mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[11]
Maraviroc	DMTL94F	Major	Decreased metabolism of Fosamprenavir caused by Maraviroc mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[12]
-----------

Coadministration of a Drug Treating the Disease Different from Fosamprenavir (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Major	Decreased metabolism of Fosamprenavir caused by Ivosidenib mediated inhibition of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[13]
Midostaurin	DMI6E0R	Moderate	Decreased metabolism of Fosamprenavir caused by Midostaurin mediated inhibition of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[14]
Arn-509	DMT81LZ	Moderate	Increased metabolism of Fosamprenavir caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[15]
Gilteritinib	DMTI0ZO	Moderate	Decreased metabolism of Fosamprenavir caused by Gilteritinib mediated inhibition of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[16]
Oliceridine	DM6MDCF	Major	Decreased metabolism of Fosamprenavir caused by Oliceridine mediated inhibition of CYP450 enzyme.	Acute pain [MG31]	[17]
Ivabradine	DM0L594	Major	Decreased metabolism of Fosamprenavir caused by Ivabradine mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[10]
Dronedarone	DMA8FS5	Major	Decreased metabolism of Fosamprenavir caused by Dronedarone mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[10]
Bedaquiline	DM3906J	Moderate	Decreased metabolism of Fosamprenavir caused by Bedaquiline mediated inhibition of CYP450 enzyme.	Antimicrobial drug resistance [MG50-MG52]	[18]
Troleandomycin	DMUZNIG	Minor	Decreased metabolism of Fosamprenavir caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[19]
Cariprazine	DMJYDVK	Major	Decreased metabolism of Fosamprenavir caused by Cariprazine mediated inhibition of CYP450 enzyme.	Bipolar disorder [6A60]	[20]
Erdafitinib	DMI782S	Major	Decreased metabolism of Fosamprenavir caused by Erdafitinib mediated inhibition of CYP450 enzyme.	Bladder cancer [2C94]	[21]
Pexidartinib	DMS2J0Z	Major	Decreased metabolism of Fosamprenavir caused by Pexidartinib mediated inhibition of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[22]
Ixabepilone	DM2OZ3G	Moderate	Decreased metabolism of Fosamprenavir caused by Ixabepilone mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[23]
HKI-272	DM6QOVN	Major	Decreased metabolism of Fosamprenavir caused by HKI-272 mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[24]
LY2835219	DM93VBZ	Moderate	Decreased metabolism of Fosamprenavir caused by LY2835219 mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[25]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Fosamprenavir caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[26]
Palbociclib	DMD7L94	Major	Decreased metabolism of Fosamprenavir caused by Palbociclib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[27]
Cabazitaxel	DMPAZHC	Moderate	Decreased metabolism of Fosamprenavir caused by Cabazitaxel mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[10]
Trastuzumab Emtansine	DMU1LXS	Moderate	Decreased metabolism of Fosamprenavir caused by Trastuzumab Emtansine mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[10]
Macitentan	DMP79A1	Major	Decreased metabolism of Fosamprenavir caused by Macitentan mediated inhibition of CYP450 enzyme.	Cardiovascular disease [BA00-BE2Z]	[28]
Vilanterol	DMF5EK1	Moderate	Decreased metabolism of Fosamprenavir caused by Vilanterol mediated inhibition of CYP450 enzyme.	Chronic obstructive pulmonary disease [CA22]	[29]
Revefenacin	DMMP5SI	Moderate	Decreased clearance of Fosamprenavir due to the transporter inhibition by Revefenacin.	Chronic obstructive pulmonary disease [CA22]	[30]
Indacaterol	DMQJHR7	Minor	Decreased metabolism of Fosamprenavir caused by Indacaterol mediated inhibition of CYP450 enzyme.	Chronic obstructive pulmonary disease [CA22]	[31]
Levomilnacipran	DMV26S8	Major	Decreased metabolism of Fosamprenavir caused by Levomilnacipran mediated inhibition of CYP450 enzyme.	Chronic pain [MG30]	[32]
Regorafenib	DMHSY1I	Moderate	Decreased metabolism of Fosamprenavir caused by Regorafenib mediated inhibition of CYP450 enzyme.	Colorectal cancer [2B91]	[10]
Drospirenone	DM1A9W3	Major	Decreased metabolism of Fosamprenavir caused by Drospirenone mediated inhibition of CYP450 enzyme.	Contraceptive management [QA21]	[10]
Ulipristal	DMBNI20	Minor	Decreased metabolism of Fosamprenavir caused by Ulipristal mediated inhibition of CYP450 enzyme.	Contraceptive management [QA21]	[16]
Osilodrostat	DMIJC9X	Major	Decreased metabolism of Fosamprenavir caused by Osilodrostat mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[16]
Ivacaftor	DMZC1HS	Major	Decreased metabolism of Fosamprenavir caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[10]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Fosamprenavir caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[33]
Rivaroxaban	DMQMBZ1	Moderate	Decreased metabolism of Fosamprenavir caused by Rivaroxaban mediated inhibition of CYP450 enzyme.	Deep vein thrombosis [BD71]	[10]
Vilazodone	DM4LECQ	Major	Decreased metabolism of Fosamprenavir caused by Vilazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[34]
Polatuzumab vedotin	DMF6Y0L	Major	Decreased metabolism of Fosamprenavir caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme.	Diffuse large B-cell lymphoma [2A81]	[35]
Ospemifene	DMC4GEI	Moderate	Decreased metabolism of Fosamprenavir caused by Ospemifene mediated inhibition of CYP450 enzyme.	Dyspareunia [GA12]	[36]
Cenobamate	DM8KLU9	Moderate	Increased metabolism of Fosamprenavir caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[15]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Fosamprenavir caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[16]
Fosphenytoin	DMOX3LB	Moderate	Increased metabolism of Fosamprenavir caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[37]
Lacosamide	DMVM6QR	Moderate	Decreased metabolism of Fosamprenavir caused by Lacosamide mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[10]
Eslicarbazepine	DMZREFQ	Moderate	Increased metabolism of Fosamprenavir caused by Eslicarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[15]
Cannabidiol	DM0659E	Minor	Decreased metabolism of Fosamprenavir caused by Cannabidiol mediated inhibition of CYP450 enzyme.	Epileptic encephalopathy [8A62]	[16]
Bay 80-6946	DMLOS5R	Moderate	Decreased metabolism of Fosamprenavir caused by Bay 80-6946 mediated inhibition of CYP450 enzyme.	Follicular lymphoma [2A80]	[38]
Tazemetostat	DMWP1BH	Major	Decreased metabolism of Fosamprenavir caused by Tazemetostat mediated inhibition of CYP450 enzyme.	Follicular lymphoma [2A80]	[39]
Solifenacin	DMG592Q	Major	Decreased metabolism of Fosamprenavir caused by Solifenacin mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[10]
Mirabegron	DMS1GYT	Minor	Decreased metabolism of Fosamprenavir caused by Mirabegron mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[40]
Dexlansoprazole	DM1DBV5	Moderate	Decreased absorption of Fosamprenavir due to altered gastric pH caused by Dexlansoprazole.	Gastro-oesophageal reflux disease [DA22]	[41]
Avapritinib	DMK2GZX	Major	Decreased metabolism of Fosamprenavir caused by Avapritinib mediated inhibition of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[16]
Colchicine	DM2POTE	Major	Decreased metabolism of Fosamprenavir caused by Colchicine mediated inhibition of CYP450 enzyme.	Gout [FA25]	[42]
ABT-450	DMFW860	Moderate	Decreased metabolism of Fosamprenavir caused by ABT-450 mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[16]
Simeprevir	DMLUA9D	Major	Decreased metabolism of Fosamprenavir caused by Simeprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[10]
Daclatasvir	DMSFK9V	Moderate	Decreased metabolism of Fosamprenavir caused by Daclatasvir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[10]
GS-9857	DMYU6P5	Moderate	Decreased clearance of Fosamprenavir due to the transporter inhibition by GS-9857.	Hepatitis virus infection [1E50-1E51]	[43]
Brentuximab vedotin	DMWLC57	Moderate	Decreased metabolism of Fosamprenavir caused by Brentuximab vedotin mediated inhibition of CYP450 enzyme.	Hodgkin lymphoma [2B30]	[16]
BMS-201038	DMQTAGO	Major	Decreased metabolism of Fosamprenavir caused by BMS-201038 mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[10]
Aliskiren	DM1BV7W	Moderate	Decreased metabolism of Fosamprenavir caused by Aliskiren mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[44]
Levamlodipine	DM92S6N	Moderate	Decreased metabolism of Fosamprenavir caused by Levamlodipine mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[44]
Tolvaptan	DMIWFRL	Major	Decreased metabolism of Fosamprenavir caused by Tolvaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[10]
Lesinurad	DMUR64T	Moderate	Increased metabolism of Fosamprenavir caused by Lesinurad mediated induction of CYP450 enzyme.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[15]
TP-434	DM5A31S	Minor	Decreased metabolism of Fosamprenavir caused by TP-434 mediated inhibition of CYP450 enzyme.	Infectious gastroenteritis/colitis [1A40]	[45]
Suvorexant	DM0E6S3	Major	Decreased metabolism of Fosamprenavir caused by Suvorexant mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[46]
Amobarbital	DM0GQ8N	Moderate	Increased metabolism of Fosamprenavir caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[15]
Tasimelteon	DMLOQ1V	Moderate	Decreased metabolism of Fosamprenavir caused by Tasimelteon mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[47]
ITI-007	DMUQ1DO	Major	Decreased metabolism of Fosamprenavir caused by ITI-007 mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[48]
Quazepam	DMY4D87	Moderate	Decreased metabolism of Fosamprenavir caused by Quazepam mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[49]
Eluxadoline	DMYZ0P1	Moderate	Decreased metabolism of Fosamprenavir caused by Eluxadoline mediated inhibition of CYP450 enzyme.	Irritable bowel syndrome [DD91]	[50]
Naloxegol	DML0B41	Major	Decreased metabolism of Fosamprenavir caused by Naloxegol mediated inhibition of CYP450 enzyme.	Large intestine motility disorder [DB32]	[10]
Pemigatinib	DM819JF	Major	Decreased metabolism of Fosamprenavir caused by Pemigatinib mediated inhibition of CYP450 enzyme.	Liver cancer [2C12]	[16]
Crizotinib	DM4F29C	Major	Decreased metabolism of Fosamprenavir caused by Crizotinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[10]
Brigatinib	DM7W94S	Major	Decreased metabolism of Fosamprenavir caused by Brigatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[51]
Ceritinib	DMB920Z	Major	Decreased metabolism of Fosamprenavir caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[10]
Lurbinectedin	DMEFRTZ	Major	Decreased metabolism of Fosamprenavir caused by Lurbinectedin mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[52]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Fosamprenavir caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[15]
Osimertinib	DMRJLAT	Major	Decreased metabolism of Fosamprenavir caused by Osimertinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[53]
BIBW 2992	DMTKD7Q	Moderate	Accelerated clearance of Fosamprenavir due to the transporter induction by BIBW 2992.	Lung cancer [2C25]	[54]
Pralsetinib	DMWU0I2	Major	Decreased metabolism of Fosamprenavir caused by Pralsetinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[55]
Capmatinib	DMYCXKL	Major	Decreased metabolism of Fosamprenavir caused by Capmatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[56]
Selpercatinib	DMZR15V	Major	Decreased metabolism of Fosamprenavir caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[16]
Artemether	DM48QOT	Major	Decreased metabolism of Fosamprenavir caused by Artemether mediated inhibition of CYP450 enzyme.	Malaria [1F40-1F45]	[10]
Hydroxychloroquine	DMSIVND	Moderate	Decreased metabolism of Fosamprenavir caused by Hydroxychloroquine mediated inhibition of CYP450 enzyme.	Malaria [1F40-1F45]	[10]
Idelalisib	DM602WT	Moderate	Decreased metabolism of Fosamprenavir caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[57]
GDC-0199	DMH0QKA	Major	Decreased metabolism of Fosamprenavir caused by GDC-0199 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[10]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Fosamprenavir caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[58]
Acalabrutinib	DM7GCVW	Major	Decreased metabolism of Fosamprenavir caused by Acalabrutinib mediated inhibition of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[59]
Ibrutinib	DMHZCPO	Major	Decreased metabolism of Fosamprenavir caused by Ibrutinib mediated inhibition of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[60]
Ponatinib	DMYGJQO	Major	Decreased metabolism of Fosamprenavir caused by Ponatinib mediated inhibition of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[10]
Vemurafenib	DM62UG5	Moderate	Decreased metabolism of Fosamprenavir caused by Vemurafenib mediated inhibition of CYP450 enzyme.	Melanoma [2C30]	[61]
Selumetinib	DMC7W6R	Major	Decreased metabolism of Fosamprenavir caused by Selumetinib mediated inhibition of CYP450 enzyme.	Melanoma [2C30]	[62]
Dabrafenib	DMX6OE3	Moderate	Decreased metabolism of Fosamprenavir caused by Dabrafenib mediated inhibition of CYP450 enzyme.	Melanoma [2C30]	[10]
Ubrogepant	DM749I3	Moderate	Decreased metabolism of Fosamprenavir caused by Ubrogepant mediated inhibition of CYP450 enzyme.	Migraine [8A80]	[63]
Rimegepant	DMHOAUG	Moderate	Decreased metabolism of Fosamprenavir caused by Rimegepant mediated inhibition of CYP450 enzyme.	Migraine [8A80]	[64]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Fosamprenavir caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[65]
Flibanserin	DM70DTN	Major	Decreased metabolism of Fosamprenavir caused by Flibanserin mediated inhibition of CYP450 enzyme.	Mood disorder [6A60-6E23]	[66]
Panobinostat	DM58WKG	Moderate	Decreased metabolism of Fosamprenavir caused by Panobinostat mediated inhibition of CYP450 enzyme.	Multiple myeloma [2A83]	[67]
Siponimod	DM2R86O	Major	Decreased metabolism of Fosamprenavir caused by Siponimod mediated inhibition of CYP450 enzyme.	Multiple sclerosis [8A40]	[10]
Deflazacort	DMV0RNS	Major	Decreased metabolism of Fosamprenavir caused by Deflazacort mediated inhibition of CYP450 enzyme.	Muscular dystrophy [8C70]	[16]
Romidepsin	DMT5GNL	Moderate	Decreased metabolism of Fosamprenavir caused by Romidepsin mediated inhibition of CYP450 enzyme.	Mycosis fungoides [2B01]	[68]
Fedratinib	DM4ZBK6	Major	Decreased metabolism of Fosamprenavir caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[16]
Nilotinib	DM7HXWT	Major	Decreased metabolism of Fosamprenavir caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[10]
Ruxolitinib	DM7Q98D	Major	Decreased metabolism of Fosamprenavir caused by Ruxolitinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[69]
Vorapaxar	DMA16BR	Major	Decreased metabolism of Fosamprenavir caused by Vorapaxar mediated inhibition of CYP450 enzyme.	Myocardial infarction [BA41-BA43]	[10]
Netupitant	DMEKAYI	Minor	Decreased metabolism of Fosamprenavir caused by Netupitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[70]
Entrectinib	DMMPTLH	Major	Decreased metabolism of Fosamprenavir caused by Entrectinib mediated inhibition of CYP450 enzyme.	Non-small cell lung cancer [2C25]	[10]
S-297995	DM26IH8	Moderate	Decreased metabolism of Fosamprenavir caused by S-297995 mediated inhibition of CYP450 enzyme.	Opioid use disorder [6C43]	[16]
Olaparib	DM8QB1D	Major	Decreased metabolism of Fosamprenavir caused by Olaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[10]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Fosamprenavir caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[71]
Istradefylline	DM20VSK	Major	Decreased metabolism of Fosamprenavir caused by Istradefylline mediated inhibition of CYP450 enzyme.	Parkinsonism [8A00]	[72]
Pimavanserin	DMR7IVC	Major	Decreased metabolism of Fosamprenavir caused by Pimavanserin mediated inhibition of CYP450 enzyme.	Parkinsonism [8A00]	[73]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Fosamprenavir caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[74]
Lefamulin	DME6G97	Major	Decreased metabolism of Fosamprenavir caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[75]
Lonafarnib	DMGM2Z6	Major	Decreased metabolism of Fosamprenavir caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[76]
ABIRATERONE	DM8V75C	Minor	Decreased metabolism of Fosamprenavir caused by ABIRATERONE mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[77]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Fosamprenavir caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[15]
Darolutamide	DMV7YFT	Minor	Decreased metabolism of Fosamprenavir caused by Darolutamide mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[78]
Silodosin	DMJSBT6	Major	Decreased metabolism of Fosamprenavir caused by Silodosin mediated inhibition of CYP450 enzyme.	Prostate hyperplasia [GA90]	[10]
Ambrisentan	DMD1QXW	Minor	Decreased metabolism of Fosamprenavir caused by Ambrisentan mediated inhibition of CYP450 enzyme.	Pulmonary hypertension [BB01]	[79]
Riociguat	DMXBLMP	Moderate	Decreased metabolism of Fosamprenavir caused by Riociguat mediated inhibition of CYP450 enzyme.	Pulmonary hypertension [BB01]	[10]
Everolimus	DM8X2EH	Major	Decreased clearance of Fosamprenavir due to the transporter inhibition by Everolimus.	Renal cell carcinoma [2C90]	[10]
Axitinib	DMGVH6N	Major	Decreased metabolism of Fosamprenavir caused by Axitinib mediated inhibition of CYP450 enzyme.	Renal cell carcinoma [2C90]	[10]
Ciclesonide	DM2NA4K	Moderate	Decreased metabolism of Fosamprenavir caused by Ciclesonide mediated inhibition of CYP450 enzyme.	Respiratory system disease [CB40-CB7Z]	[80]
Upadacitinib	DM32B5U	Major	Decreased metabolism of Fosamprenavir caused by Upadacitinib mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[81]
Tofacitinib	DMBS370	Major	Decreased metabolism of Fosamprenavir caused by Tofacitinib mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[10]
Iloperidone	DM6AUFY	Major	Decreased metabolism of Fosamprenavir caused by Iloperidone mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[82]
Avanafil	DM75CXN	Major	Decreased metabolism of Fosamprenavir caused by Avanafil mediated inhibition of CYP450 enzyme.	Sexual dysfunction [HA00-HA01]	[83]
Voxelotor	DMCS6M5	Major	Decreased metabolism of Fosamprenavir caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[84]
LDE225	DMM9F25	Major	Decreased metabolism of Fosamprenavir caused by LDE225 mediated inhibition of CYP450 enzyme.	Skin cancer [2C30-2C37]	[85]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Fosamprenavir caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[16]
Larotrectinib	DM26CQR	Major	Decreased metabolism of Fosamprenavir caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[10]
Trabectedin	DMG3Y89	Major	Decreased metabolism of Fosamprenavir caused by Trabectedin mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[10]
Armodafinil	DMGB035	Moderate	Increased metabolism of Fosamprenavir caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[37]
LEE011	DMMX75K	Major	Decreased metabolism of Fosamprenavir caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[16]
Pitolisant	DM8RFNJ	Moderate	Increased metabolism of Fosamprenavir caused by Pitolisant mediated induction of CYP450 enzyme.	Somnolence [MG42]	[16]
Pomalidomide	DMTGBAX	Moderate	Decreased metabolism of Fosamprenavir caused by Pomalidomide mediated inhibition of CYP450 enzyme.	Systemic sclerosis [4A42]	[10]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Fosamprenavir caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[86]
As-1670542	DMV05SW	Moderate	Decreased metabolism of Fosamprenavir caused by As-1670542 mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[16]
Apixaban	DM89JLN	Moderate	Decreased metabolism of Fosamprenavir caused by Apixaban mediated inhibition of CYP450 enzyme.	Thrombosis [DB61-GB90]	[16]
Brilinta	DMBR01X	Moderate	Decreased metabolism of Fosamprenavir caused by Brilinta mediated inhibition of CYP450 enzyme.	Thrombosis [DB61-GB90]	[16]
Cabozantinib	DMIYDT4	Major	Decreased metabolism of Fosamprenavir caused by Cabozantinib mediated inhibition of CYP450 enzyme.	Thyroid cancer [2D10]	[10]
Saxagliptin	DMGXENV	Moderate	Decreased metabolism of Fosamprenavir caused by Saxagliptin mediated inhibition of CYP450 enzyme.	Type 2 diabetes mellitus [5A11]	[16]
Elagolix	DMB2C0E	Moderate	Increased metabolism of Fosamprenavir caused by Elagolix mediated induction of CYP450 enzyme.	Uterine fibroid [2E86]	[15]
Fluticasone	DMGCSVF	Major	Decreased metabolism of Fosamprenavir caused by Fluticasone mediated inhibition of CYP450 enzyme.	Vasomotor/allergic rhinitis [CA08]	[87]
-----------


⏷ Show the Full List of 139 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Carmellose sodium	E00625	Not Available	Disintegrant
Eisenoxyd	E00585	56841934	Colorant
Hypromellose	E00634	Not Available	Coating agent
Magnesium stearate	E00208	11177	lubricant
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
--------------------


⏷ Show the Full List of 8 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Fosamprenavir 700 mg tablet	700 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Approved antiretroviral drugs. Antiretroviral Drugs. Company report of AVERT. 2009.
2	BDDCS applied to over 900 drugs
3	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
5	Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in ... J Antimicrob Chemother. 2009 Aug;64(2):398-410.
6	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
7	Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Clin Pharmacokinet. 2006;45(2):137-68.
8	Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
9	Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
10	Cerner Multum, Inc. "Australian Product Information.".
11	Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
12	Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.
13	Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
14	Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
15	Acosta EP, Henry K, Baken L, Page LM, Fletcher CV "Indinavir concentrations and antiviral effect." Pharmacotherapy 19 (1999): 708-12. [PMID: 10391416]
16	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
17	Product Information. Olinvyk (oliceridine). Trevena Inc, Chesterbrook, PA.
18	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
19	Polk RE, Crouch MA, Israel DS, et al. "Pharmacokinetic interaction between ketoconazole and amprenavir after single doses in healthy men." Pharmacotherapy 19 (1999): 1378-84. [PMID: 10600086]
20	Product Information. Vraylar (cariprazine). Actavis Pharma, Inc., Parsippany, NJ.
21	Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
22	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
23	Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
24	Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D "Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects." Br J Clin Pharmacol 71 (2011): 522-7. [PMID: 21395644]
25	Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
26	Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
27	Product Information. Ibrance (palbociclib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
28	Product Information. Opsumit (macitentan). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
29	Product Information. Breo Ellipta (fluticasone-vilanterol). GlaxoSmithKline, Research Triangle Park, NC.
30	Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
31	Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
32	Product Information. Fetzima (levomilnacipran). Forest Pharmaceuticals, St. Louis, MO.
33	Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
34	Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT.
35	Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
36	Product Information. Osphena (ospemifene). Shionogi USA Inc, Florham Park, NJ.
37	Barry M, Gibbons S, Back D, Mulcahy F "Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations." Clin Pharmacokinet 32 (1997): 194-209. [PMID: 9084959]
38	Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
39	Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
40	Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
41	Product Information. Lexiva (fosamprenavir). GlaxoSmithKline, Research Triangle Park, NC.
42	Akdag I, Ersoy A, Kahvecioglu S, Gullulu M, Dilek K "Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure." J Nephrol 19 (2006): 515-7. [PMID: 17048210]
43	Product Information. Vosevi (sofosbuvir/velpatasvir/voxilaprevir). Gilead Sciences, Foster City, CA.
44	Canadian Pharmacists Association.
45	Product Information. Xerava (eravacycline). Tetraphase Pharmaceuticals, Inc, Watertown, MA.
46	Product Information. Belsomra (suvorexant). Merck & Company Inc, Whitehouse Station, NJ.
47	Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
48	Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
49	Product Information. Agenerase (amprenavir). Glaxo Wellcome, Research Triangle Pk, NC.
50	Product Information. Viberzi (eluxadoline). Actavis Pharma, Inc., Parsippany, NJ.
51	Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
52	Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
53	Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
54	Product Information. Gilotrif (afatinib). Boehringer Ingelheim, Ridgefield, CT.
55	Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
56	Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
57	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
58	Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
59	Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
60	Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA.
61	Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
62	Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
63	Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
64	Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
65	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
66	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
67	Hamberg P, Woo MM, Chen LC, et al. "Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor." Cancer Chemother Pharmacol 68 (2011): 805-13. [PMID: 21706316]
68	Product Information. Istodax (romidepsin). Gloucester Pharmaceuticals, Cambridge, MA.
69	Product Information. Jakafi (ruxolitinib). Incyte Corporation, Wilmington, DE.
70	Product Information. Akynzeo (netupitant-palonosetron). Eisai Inc, Woodcliff Lake, NJ.
71	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
72	Product Information. Nourianz (istradefylline). Kyowa Kirin, Inc, Bedminster, NJ.
73	Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
74	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
75	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
76	Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
77	Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
78	Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
79	Product Information. Letairis (ambrisentan). Gilead Sciences, Foster City, CA.
80	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
81	Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.
82	Product Information. Fanapt (iloperidone). Vanda Pharmaceuticals Inc, Rockville, MD.
83	Product Information. Stendra (avanafil). Vivus Inc, Mountain View, CA.
84	Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
85	Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
86	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
87	Arrington-Sanders R, Hutton N, Siberry GK "Ritonavir-fluticasone interaction causing Cushing syndrome in HIV-infected children and adolescents." Pediatr Infect Dis J 25 (2006): 1044-1048. [PMID: 17072128]